By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Anixa Biosciences, Inc.

Anixa Biosciences, Inc. (ANIX)

NASDAQ Currency in USD
$144.00
+$0.56
+0.39%
Last Update: 18 Jul 2026, 11:31
$4.67bn
Market Cap
-482.74
P/E Ratio (TTM)
Forward Dividend Yield
$105.50-$184.25
52 Week Range

ANIX Stock Price Chart

Explore Anixa Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze ANIX price movements and trends.

ANIX Company Profile

Discover essential business fundamentals and corporate details for Anixa Biosciences, Inc. (ANIX) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

7 Oct 1983

Employees

5.00

CEO

Amit Kumar

Description

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.

ANIX Financial Timeline

Browse a chronological timeline of Anixa Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 10 Sept 2026

EPS estimate is -$0.08.

Earnings released on 10 Jun 2026

EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.

Earnings released on 9 Mar 2026

EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.

Earnings released on 12 Jan 2026

EPS came in at -$0.09 falling short of the estimated -$0.09 by -2.31%.

Earnings released on 10 Sept 2025

EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.

Earnings released on 28 May 2025

EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%.

Earnings released on 11 Mar 2025

EPS came in at -$0.10 matching the estimated -$0.10.

Earnings released on 10 Jan 2025

EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.18%.

Earnings released on 6 Sept 2024

EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%.

Earnings released on 4 Jun 2024

EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%.

Earnings released on 12 Mar 2024

EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%.

Earnings released on 16 Jan 2024

EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $156.00k .

Earnings released on 6 Sept 2023

EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.

Earnings released on 14 Jun 2023

EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%, while revenue for the quarter reached $210.00k .

Earnings released on 16 Mar 2023

EPS came in at -$0.08 surpassing the estimated -$0.16 by +50.00%.

Earnings released on 4 Jan 2023

EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $2.47bn .

Earnings released on 9 Sept 2022

EPS came in at -$0.09 surpassing the estimated -$0.13 by +30.77%.

Earnings released on 10 Jun 2022

EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%.

Earnings released on 11 Mar 2022

EPS came in at -$0.13 matching the estimated -$0.13.

Earnings released on 4 Jan 2022

EPS came in at -$0.13 , while revenue for the quarter reached $3.61m .

Earnings released on 1 Sept 2021

EPS came in at -$0.14 falling short of the estimated -$0.08 by -75.00%.

ANIX Stock Performance

Access detailed ANIX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run